Glioblastoma Multiforme: In-depth analysis of key marketed drugs.
By Joseph Hedden, Senior Analyst
25 July 2014
I am an analyst at Datamonitor Healthcare, having previously completed a PhD in Structural and Molecular Biology at Univ...
Read full bio
Temodar (temozolomide) is set to remain the standard of care pharmacological therapy for glioblastoma multiforme (GBM). Although brand sales will continue to decline now that generics are gaining traction in the US and EU, temozolomide will remain central to current and potential future treatment regimens. Datamonitor Healthcare has analyzed the key marketed drugs in GBM across the US, Japan, and five major EU markets, including clinical data and a comparative evaluation of clinical and commercial drug attributes.
How will our GBM marketed drugs report benefit you?
- Benchmark your product Understand why Temodar will continue to be the central treatment for GBM through an analysis of clinical and commercial attributes, allowing you to understand the criteria that future products will need to meet in order to gain approval and enjoy success in the market.
- Avoid potential risks Understand why Avastin (bevacizumab) has not secured EMA approval for the treatment of GBM to identify and avoid potential risks in GBM drug development.
- Identify investment opportunity Explore which therapies are approved in different patient populations and in each market, allowing you to identify unmet need and where opportunities may lie.
Key questions answered
- How will the EMA’s rejection of two marketing applications for Avastin in GBM affect its likelihood of EU approval?
- Why are there questions regarding Avastin’s efficacy in GBM?
- Will Avastin and Temodar face competition from pipeline therapies?
|Drug List:||Companies Mentioned:|
Posted in Oncology.